Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”).

On May 27, 2024, the Court granted an order (the “SISP Order”) which i) approved a sale and investment solicitation process to be conducted in respect of the business and/or assets of the Company (the “SISP”), and ii) approved the agreement of purchase and sale between IntelGenx, as vendor, and atai Life Sciences AG, as purchaser, solely for the purpose of constituting the “stalking horse” bid under the SISP (the “Stalking Horse Bid”). The Stalking Horse Bid establishes a baseline price and deal structure for the solicitation of superior bids from qualified interested parties and provides certainty that a going-concern solution for the business of IntelGenx has already been identified.

Ernst & Young Orenda Corporate Finance Inc. and its affiliate, Ernst & Young Corporate Finance (Canada) Inc. shall be assisting the Company and the Monitor in connection with the SISP process.

The SISP is a two-phased process with the Phase 1 bid deadline set for July 15, 2024. Parties interested in the opportunity should contact the Monitor via one of the persons listed below to get further details.

Jatinder Wadhwa(1)
Senior Vice President
+1 416 943 3078
[email protected]

Mansa Singh
Senior Associate
+1 416 932 4902
[email protected]
Jessica Jingwei
+1 416 932 4424
[email protected]
Martin Rosenthal
Senior Vice President
+1 514 879 6549
[email protected]
Martin Carrière
Senior Vice President
+1 514 879 3254
Alexandre Ferland
+1 514 943 0929
[email protected]

Copies of the SISP Order and the SISP procedures may be obtained from the website of the Monitor at

(1) Any inquiries by U.S. persons should be directed to Ernst & Young Corporate Finance (Canada) Inc. through Jatinder Wadhwa.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm® and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit and connect with us on X and LinkedIn.

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).